Publications
2025
Bolla M., Colombo G., Falappa M., Pace M., Baravalle R., Martinez N., Montani F., Tucci V., Cancedda L.
NKCC1 inhibition improves sleep quality and EEG information content in a Down syndrome mouse model
iScience, vol. 28, (no. 4)
2024
Ruiz Munevar M.J., Rizzi V., Portioli C., Vidossich P., Cao E., Parrinello M., Cancedda L., De Vivo M.
Cation Chloride Cotransporter NKCC1 Operates through a Rocking-Bundle Mechanism
Journal of the American Chemical Society, vol. 146, (no. 1), pp. 552-566
2024
Potenzieri A., Uccella S., Preiti D., Pisoni M., Rosati S., Lavarello C., Bartolucci M., Debellis D., Catalano F., Petretto A., Nobili L., Fellin T., Tucci V., Ramenghi L.A., Savardi A., Cancedda L.
Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target
Science advances, vol. 10, (no. 9)
2024
Colombi I., Rastogi M., Parrini M., Alberti M., Potenzieri A., Chellali M.M., Rosati S., Chiappalone M., Nanni M., Contestabile A., Cancedda L.
Heterogeneous subpopulations of GABAAR-responding neurons coexist across neuronal network scales and developmental stages in health and disease
iScience, vol. 27, (no. 4)
2024
Rastogi M., Bartolucci M., Nanni M., Aloisio M., Vozzi D., Petretto A., Contestabile A., Cancedda L.
Integrative multi-omic analysis reveals conserved cell-projection deficits in human Down syndrome brains
Neuron
2024
Marinaro G., Bruno L., Pirillo N., Coluccio M.L., Nanni M., Malara N., Battista E., Bruno G., De Angelis F., Cancedda L., Di Mascolo D., Gentile F.
The role of elasticity on adhesion and clustering of neurons on soft surfaces
Communications Biology, vol. 7, (no. 1)
2023
Smith J.B., Cancedda L., Jozwiak S., Mercer A.C.
Editorial: Viral vector-based gene therapy in neurological disease: The future is now
Frontiers in Neurology, vol. 14
2023
Savardi A., Patricelli Malizia A., De Vivo M., Cancedda L., Borgogno M.
Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders
ACS Pharmacology and Translational Science, vol. 6, (no. 1), pp. 1-11
2022
Cwetsch A.W., Ziogas I., Narducci R., Savardi A., Bolla M., Pinto B., Perlini L.E., Bassani S., Passafaro M., Cancedda L.
A rat model of a focal mosaic expression of PCDH19 replicates human brain developmental abnormalities and behaviours
Brain Communications, vol. 4, (no. 3)
2022
Savardi A., Malizia A.P., De Vivo M., Cancedda L., Borgogno M.
Preclinical development of the NKCC1 inhibitor ARN23746 for the treatment of neurodevelopmental disorders
ACS Pharmacology & Translational Science
Article in Press
Journal
2022
Zhao Y., Roy K., Vidossich P., Cancedda L., De Vivo M., Forbush B., Cao E.
Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide
Nature Communications, vol. 13, (no. 1)
2021
Cancedda L.
Associate Editor
Frontiers in Neurodevelopment
Editorial
Journal
2021
Portioli C., Ruiz Munevar M.J., De Vivo M., Cancedda L.
Cation-coupled chloride cotransporters: chemical insights and disease implications
Trends in Chemistry, vol. 3, (no. 10), pp. 832-849
2021
Borgogno M., Savardi A., Manigrasso J., Turci A., Portioli C., Ottonello G., Bertozzi S.M., Armirotti A., Contestabile A., Cancedda L., De Vivo M.
Design, Synthesis,In VitroandIn VivoCharacterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in down Syndrome
Journal of Medicinal Chemistry, vol. 64, (no. 14), pp. 10203-10229
2021
Savardi A., Borgogno M., De Vivo M., Cancedda L.
Pharmacological tools to target NKCC1 in brain disorders
Trends in Pharmacological Sciences, vol. 42, (no. 12), pp. 1009-1034